Cargando…
Progress in the risk assessment of hydroxychloroquine in frail elderly people
Hydroxychloroquine (HCQ) is an antimalarial drug also known to have anti‐inflammatory and antiviral effects. The antiviral action of HCQ has been a point of interest for many researchers because of its mechanism of action and the potential use it could have during the current COVID‐19 pandemic. Howe...
Autores principales: | Castagna, Alberto, Ruotolo, Giovanni, Manzo, Ciro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7954841/ https://www.ncbi.nlm.nih.gov/pubmed/33738381 http://dx.doi.org/10.1002/agm2.12140 |
Ejemplares similares
-
Hydroxychloroquine and QT Prolongation in Older Patients with Rheumatic Diseases: Who is afraid of the Boogeyman? We are not!
por: Castagna, Alberto, et al.
Publicado: (2020) -
Psychomotor Agitation Following Treatment with Hydroxychloroquine
por: Manzo, Ciro, et al.
Publicado: (2017) -
Can SARS-CoV-2 trigger relapse of polymyalgia rheumatica?
por: Manzo, Ciro, et al.
Publicado: (2021) -
Answer to Cadiou et al. “SARS-CoV-2, polymyalgia rheumatica and giant cell arteritis: COVID-19 vaccine shot as a trigger?”. Joint Bone Spine 2021;88:105282
por: Manzo, Ciro, et al.
Publicado: (2022) -
COVID‐19 and cardiovascular problems in elderly patients: Food for thought
por: Costa, Raffaele, et al.
Publicado: (2021)